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Summary Acute generalized exanthematous pustulo-
sis is a rare disorder characterized by an acute onset 
of generalized, nonfollicular, pustular eruption associ-
ated with fever. It is usually drug-induced and is uncom-
mon in children. We report a 12-year-old girl with acute 
generalized exanthematous pustulosis induced by oral 
ketoconazole. To our knowledge, in spite of its rela-
tively frequent use, acute generalized exanthematous 
pustulosis due to ketoconazole has not been previously 
reported.
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IntroduCtIon
The term acute generalized exanthematous 
pustulosis (AGEP) was first introduced by Beylot 
et al. in 1980 (1) to describe a pustular eruption 
characterized by an acute onset after an infection 
and/or drug ingestion in subjects with no history of 
psoriasis, evolution towards spontaneous healing 
after a single attack, and existence of a marked 
dermal vasculitis in addition to nonfollicular sub-
corneal sterile pustules (2,3). We report the occur-
rence of AGEP as the result of ketoconazole use. 
To our knowledge, this is the first reported case of 
ketoconazole-induced AGEP.
CaSe report
A 12-year-old girl with a one-year medical his-
tory of dermatomyositis was evaluated for the 
sudden onset of high fever and a widespread ery-
thematous rash of 5-days duration. Soon multiple, 
small pustules covered her trunk and extremities. 
The child had been on methylprednisolone thera-
py for one year from the onset of dermatomyositis 
with initial dose of 40 mg daily. Methylpredniso-
lone had been gradually tapered and a mainte-
nance dose of 4 mg daily had been established 
for 15 days prior to the current presentation and 
was continued during and after AGEP episode. 
One day before the onset of fever and rash, only 
ketoconazole 200 mg/day was prescribed as pro-
phylactic therapy for oral candidiasis.
On physical examination, fever was detected 
(38.8 ºC). Numerous erythematous and edema-
tous patches with superficial, nonfollicular pus-
tules were evident over the trunk and extremities 
(Fig. 1). Mucous membranes and her nails were 
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spared. Results of laboratory evaluation revealed 
white blood cell count of 21×109/L (NR 4.5-9×109/
L), with neutrophil count 12.2×109/L (NR 2-6×109/
L) and erythrocyte sedimentation rate (ESR) of 28 
mm/h. Liver function tests, urea, creatinine, elec-
trolytes, and serum calcium level were within the 
normal limits. Viral serology, C-reactive protein, 
antistreptolysin 0 titers and bacteriologic studies 
of pustules were negative.
Histological examination of the skin revealed a 
large subcorneal pustule and moderate acantho-
sis. The papillary dermis was edematous with a 
mixed perivascular inflammatory cell infiltrate of 
lymphocytes, neutrophils, and a few eosinophils. 
In some areas, leukocytoclastic vasculitis was ob-
served. The endothelial cells appeared swollen; 
the blood vessels had decreased lumens (Fig. 2).
The treatment with ketoconazole was stopped. 
However, methylprednisolone 4 mg daily was con-
tinued as to maintain dermatomyositis during and 
after AGEP episode. Symptomatic treatment with 
topical 0.1% hydrocortisone-17-butyrate cream 
and levocetirizine 5 mg daily was initiated.
dISCuSSIon
Acute generalized exanthematous pustulosis 
is a rare, rapidly evolving dermatosis character-
ized by numerous small, sterile nonfollicular pus-
tules arising on a widespread edematous erythe-
ma, accompanied by high fever (temperature >38 
ºC), and neutrophilia of >7×109/L. More than 50% 
of patients have other cutaneous signs, including 
purpura, vesiculobullae, target-like lesions, and 
mucous membrane involvement (2). In extensive 
cases, a positive Nikolsky sign has been observed 
(2,3). Characteristic laboratory findings include 
an elevated total blood cell count, which is usu-
ally predominantly neutrophilic (7×109/L). Eosino-
philia may also be present. Hypocalcemia is less 
frequent, mainly related to hypoalbuminemia and 
renal failure (2). The main histopathologic find-
ings in AGEP are spongiform superficial pustules. 
Papillary dermal edema, polymorphous perivas-
cular infiltrates with eosinophils, leukocytoclastic 
vasculitis, and necrotic keratinocytes are variably 
present (2). Pustular eruption of necrotizing vas-
culitis, Sneddon-Wilkinson disease, staphylococ-
cal scalded skin syndrome, and toxic epidermal 
necrolysis can be distinguished more easily on the 
clinicopathologic basis. The pathogenetic basis of 
AGEP remains to be clarified, although T cells 
seem to play a crucial role (3).
The most frequent triggers of AGEP are medi-
cation, specifically ß-lactam antibiotics, macro-
lides, vancomycin, doxycycline, diltiazem, nifedip-
Figure 1. Close-up view of numerous superficial, non-
follicular pustules arising on a widespread erythema-
tous base.
Figure 2. Subcorneal pustule, moderate acanthosis 
and edematous papillary dermis. HE x 40
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ine, quinidine, anti-HIV protease inhibitors, non-
steroidal anti-inflammatory drugs, and corticoste-
roids (2-6). Other, less common causes of AGEP 
are enterovirus, adenovirus, Epstein-Barr virus, 
cytomegalovirus, hepatitis B virus, mycoplasma 
pneumoniae, and hypersensitivity to mercury 
(2,6). Oral corticosteroids have been implicated in 
AGEP (6). In our case, the possibility that meth-
ylprednisolone could be a mitigating or modifying 
factor should be excluded as the patient had been 
on systemic corticosteroid therapy for one year to 
maintain dermatomyositis under control.  
AGEP is remarkable for its rapid evolution with 
spontaneous resolution of pustules in less than 15 
days (2). It is also more common in women than men, 
and unusual in children (6), although it was recently 
described in 20 Chinese children, attributed mainly 
to antibiotics, sulfonamides, antipyretic analgesics 
and vaccines (7), and in a pregnant woman (8).
AGEP has been reported with the systemic 
antimycotics fluconazole (9), terbinafine (10,11), 
itraconazole (12,13) and nystatin (14). As far as 
we are aware, there have been no reports of its 
occurrence with the use of ketoconazole. Keto-
conazole itself is a highly safe agent, although it is 
possible that, due to its widespread use, a hyper-
sensitivity reaction, especially AGEP, may appear. 
Ketoconazole-induced allergic reactions are in-
frequent and usually consist of urticaria, rash and 
pruritus. In a small number of cases, ketoconazole 
triggered angioedema. Major allergic reactions, in-
cluding anaphylaxis, have been reported (15).
In our case, the diagnosis of AGEP induced 
by ketoconazole was established based upon the 
history of recent ingestion, clinical presentation, 
clinical course, and laboratory and histologic find-
ings. We consider the occurrence of dermatomyo-
sitis to be incidental, with AGEP as a drug reaction 
to oral ketoconazole. Patch testing may be used to 
diagnose drug-induced AGEP (16), but it has the 
potential to trigger the original generalized eruption 
(17,18). Therefore, patch test was not performed 
in our case. Recently, an in vitro γ-interferon re-
lease test has been used to diagnose AGEP, but its 
role remains investigational (5). Although the child 
described herein responded well to 0.1% hydro-
cortisone-17-butyrate cream and levocetirizine, in 
severe cases systemic steroids may be employed 
and the use of cyclosporine considered (19).
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Innoxa – put your skin in ‘milky’ condition; year 1929.
(From the collection of Mr. Zlatko Puntijar)
